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Plasma lipid profile associates with 
the improvement of psychological 
well-being in individuals with 
perceived stress symptoms
Stefania noerman  1, Anton Klåvus1, Elina Järvelä-Reijonen1, Leila Karhunen1, Seppo Auriola2,3, 
Riitta Korpela4, Raimo Lappalainen5, Urho M. Kujala  6, Sampsa puttonen  7,  
Marjukka Kolehmainen  1,8* & Kati Hanhineva1,3,8
Psychological stress is a suggested risk factor of metabolic disorders, but molecular mediators are not 
well understood. We investigated the association between the metabolic profiles of fasting plasma 
and the improvement of psychological well-being using non-targeted liquid chromatography-mass 
spectrometry (LC-MS) platform. The metabolic profiles of volunteers participating in the face-to-face 
intervention group (n = 60) in a randomised lifestyle intervention were compared to ones of controls 
(n = 64) between baseline and 36-week follow-up. Despite modest differences in metabolic profile 
between groups, we found associations between phosphatidylcholines (PCs) and several parameters 
indicating stress, adiposity, relaxation, and recovery. The relief of heart-rate-variability-based stress 
had positive, while improved indices of recovery and relaxation in the intervention group had an 
inverse association with the reduction of e.g. lysophosphatidylcholines (LPC). Interleukin-1 receptor 
antagonist and adiposity correlated positively with the suppressed PCs and negatively with the 
elevated plasmalogens PC(P-18:0/22:6) and PC(P-18:0/20:4). Also, we found changes in an unknown 
class of lipids over time regardless of the intervention groups, which also correlated with physiological 
and psychological markers of stress. The associations between lipid changes with some markers of 
psychological wellbeing and body composition may suggest the involvement of these lipids in the 
shared mechanisms between psychological and metabolic health.
The co-existence of psychological stress with higher adiposity1 and obesity2 has nominated stress as an essen-
tial determinant of health. In a physiological context, stress has been associated with hypertension3, alteration 
of blood glucose and lipid profiles4, elevated blood pressure, heart rate, and fibrinogen responses5, suggesting 
stress as a risk factor of metabolic disorders6,7. The biological mechanisms linking psychological stress with 
atherosclerosis and obesity8 have been previously proposed, including inflammation and altered activity of the 
hypothalamic-pituitary-adrenal (HPA) axis or neuroendocrine pathway1.
In addition to the biological implications, psychological stress has also been linked to detrimental 
health-related habits or lifestyle leading to health deterioration, including increased smoking9 and alcohol intake2. 
Furthermore, stress has been accompanied by unfavourable eating behaviours, such as emotional10, uncontrolled 
eating, and higher frequency of binge eating11. Stress has also been associated with a poor dietary quality1, 
reflected by higher intake of fast-food and calorie derived from saturated fat and sugar2,11–13, and lower consump-
tion of fruits, vegetables, legumes, and whole grains11. Thus, the contribution of psychological stress to obesity 
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or other metabolic disturbances cannot rule out behavioural changes. This complex interaction hence provides a 
challenge8 to fully comprehend the causal relationship between psychological well-being and metabolic health in 
a perspective of the human body as a system. Therefore, there is a need to clarify this relationship to enable more 
effective prevention of both obesity and psychological stress.
One of the ways to elucidate the relationship is by assessing the implication of psychological stress in the sys-
temic circulation. Several experimental studies have previously shown how the profile of blood metabolites could 
reflect behavioural symptoms. In mice, stress has been indicated by higher plasma levels of 4-hydroxyproline, 
3-aminopropanoic acid, orotic acid, and lower urea, dihydroxyacetone, ribose, lactic acid, and glycerol14. In 
dogs, behavioural scores similar to attention-deficit/hyperactivity disorder have been associated positively with 
kynurenic acid, fatty acids (20:4) and (18:1), and negatively with phospholipids and microbial metabolites of 
tryptophan such as indole acetic acid and 3-indolepropionic acid15. In humans, similarly, kynurenine and indoxyl 
sulfate have been associated with a personality trait prone to psychological stress16. Depression has been marked 
by a lower plasma level of medium-chain fatty acids17 and the ratio between fatty acids (20:4) and (22:5), inde-
pendent of dietary consumption of n-3 or n-6 fatty acids18.
Elixir study was a multi-centre lifestyle intervention aimed to enhance the psychological well-being of 339 
individuals with overweight/obesity and self-reported stress symptoms19. In this study, higher perceived stress 
was associated with less physical activity20 and unfavourable eating behaviours, such as higher dependency on 
emotional and rewarding properties of food rather than physiological hunger cues and less consumption of 
wholegrain products21. Conversely, study participants with higher physical activity recovered better from stress22. 
Considering these results, we aimed to examine whether the improvement of psychological well-being in the 
volunteers of the Elixir study is associated with specific profiles of circulating metabolites that would indicate 
both subjective and objective measures of psychological well-being. We investigated the metabolic profiles in the 
volunteers of the control, as well as of the face-to-face intervention group (Fig. 1) representing the group with 
the most noticeable improvement of their psychological stress levels among other intervention groups23. In this 
report, we show how specific plasma metabolites reflect changes in psychological well-being and body composi-
tion, which may assist further studies aiming to elucidate the causal mechanisms linking psychological well-being 
and metabolic health.
Results
Body composition and lifestyle indicators. Within this subset of the 8-week lifestyle intervention study, 
the participants in the intervention (n = 60) and control groups (n = 64) had a similar distribution of gender, 
seasons of enrollment, and research centres (Table 1). The body composition and distribution of lifestyle features 
(alcohol consumption, smoking, and physical activity) at baseline were similar, too (Table 1).
After the follow-up (week 36), both intervention and control groups within this substudy showed changes 
in their body composition, marked by the reduction of body weight, BMI, waist circumference, and body fat 
percentage, but the changes did not differ between the groups (Table 1). At the follow-up, the alcohol consump-
tion based on AUDIT-C questionnaire was reduced in both groups so that the changes between the groups were 
not significantly different (p between-group difference for changes = 0.493). The smoking habit did not change 
in either of the groups. Compared to the control group, the intervention group had more leisure-time physical 
activity (LTPA) at the follow-up (p between-group difference = 0.004), though the change in LTPA did not seem 
to reach statistical significance (p change within intervention group = 0.521) nor lead to between-group differ-
ence (p between-group difference for changes = 0.912). The effect sizes for the reduction of adiposity, alcohol 
consumption, and increased physical activity were considered medium (Cohen’s D < −0.25).
Sleep, stress assessment, and inflammation markers. Because the medications containing alpha- 
and beta-blockers may potentially affect heart rate variability (HRV), 7 and 6 volunteers using such medicines 
(Table 1) were excluded in all analyses using objective HRV-based stress measurements from the intervention and 
control groups, respectively (Fig. 1). Therefore, the results with HRV-based parameters concerned 53 volunteers 
in the intervention and 58 volunteers in the control group.
Based on the subjective Perceived Stress Scale (PSS) questionnaire, the stress levels decreased in both groups, 
but the differences between the groups were not significant (p between-group difference for changes = 0.271) 
(Table 2). Psychological flexibility, as indicated by the inversely-scaled Acceptance and Action Questionnaire 
for Weight-related difficulties (AAQW), improved in both groups, and the reduction in the intervention group 
was higher than in the control group (p = 0.013), as also indicated by the large effect size (Cohen’s D = -0.554). 
The increased HRV-based index of stress in the control group (p = 0.037) indicated higher stress in the control 
group at the follow-up, making the changes significantly different from the intervention group (p = 0.014, Cohen’s 
D = -0.400). The HRV-based relaxation index increased more (p = 0.012) in the intervention group than in the 
control group (p for between-group changes = 0. 039, Cohen’s D = 0.162), along with a trend of elevated average 
Root Mean Square of the Successive R-R Differences (RMSSD) (p change within the intervention group = 0.033, 
p changes between groups = 0.052), showing tendency of better relaxation processes in the intervention group 
(Table 2). The sleep duration, efficiency, and quality did not change in the intervention group, though the con-
trol group seemed to improve their sleep efficiency (p changes within control group = 0.043) due to lower sleep 
efficiency at baseline (p differences between groups = 0.035). Highly sensitive C-reactive protein (hsCRP) was 
the only inflammation marker with a significant reduction within the intervention group (p = 0.023), but the 
between-group difference for the change did not reach statistical significance (p = 0.176) (Table 2).
The correlation between metabolites and physiological and psychological parameters. The 
linear mixed model with the interaction between time and intervention as the main result did not give any sta-
tistically differential features after the Benjamini-Hochberg false discovery rate (FDR) based on the number of 
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unannotated features (n = 2800) (Supplementary Fig. 1). However, our earlier analyses have shown that the inter-
vention group had the most pronounced differences in psychological flexibility23, and hence we proceeded to cor-
relate the nominally differential metabolites (unadjusted p < 0.05) to evaluate whether the participants’ metabolite 
profiles were associated with the changes in stress-related measurements conducted during the study. Among 104 
nominally differential features with unadjusted p < 0.05, many of the metabolites were not identifiable due to low 
signal intensities, resulting in lack of MS/MS data. After removal of redundant features, we identified 27 metabo-
lites, 17 of them belonged to the PC class (Supplementary Table S1). Concurrent with the high prevalence of PC 
identified, glycerophospholipid metabolism topped the chart of pathway analysis with FDR 0.003 (Supplementary 
Table S2). The correlation analyses were hence performed on these 27 identified metabolites.
Figure 1. Working flowchart of metabolomics approach on sample collection of Elixir study. HRV: heart-rate 
variability.
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Along with the reduction of adiposity, including % body fat, body weight, BMI, waist circumference (Table 1), 
plasmalogens PC(P-18:0/22:6) and PC(P-18:0/20:4) increased in the intervention group, and correlated nega-
tively with adiposity indicators (Cluster A, Fig. 2). In particular, PC(P-18:0/20:4) also inversely correlated with 
HRV-based stress index and the inverse-scaled AAQW, which showed improvement of psychological flexibil-
ity. Another elevated PC in the intervention group, PC(18:1/22:6), correlated positively with average RMSSD, 
recovery and relaxation indices (Cluster A, Fig. 2), along with the improvement of relaxation index and average 
RMSSD in the intervention group (Table 2).
The improvement of stress indicators in the intervention group (Table 2) went along with the suppressed 
LPC(14:0), (16:1), and (20:4) since those LPCs correlated positively with stress and inversely with recovery indi-
ces and average RMSSD (Cluster B, Fig. 2). The improved indicators of adiposity (Table 1) and AAQW (Table 2) 
in the intervention group had a positive correlation with the suppression of PC(16:0/16:1), (18:0/20:3), and an 
unknown metabolite 925.600@13.22 at RP negative (Cluster C, Fig. 2). Also, these suppressed lipids correlated 
positively with inflammation marker interleukin-1 receptor antagonist (IL-1Ra) and negatively with relaxation 
index. Within the same cluster, the suppressed LPC(22:5) had a positive correlation with BMI, body fat, IL-1Ra, 
and hsCRP (Fig. 2).
Phosphocholine and other down-regulated LPCs were associated positively with HMW adiponec-
tin and inversely with indicators of inflammation and body composition (Cluster D, Fig. 2). Because these 
down-regulated metabolites may be attributable to the increased levels in the control group, this correlation was 
most likely related to the improvement in the control group (Table 1).
The metabolites that changed similarly in both intervention and control groups. The p distri-
bution for the effect of time was skewed towards small p-values compared to the uniform distribution of random 
p-values expected under the null hypothesis (Supplementary Fig. S1). 36 features had FDR < 0.05, which were 
refined to 13 features with RT >1 min. They increased in both groups by time and were lipids, except for one 
metabolite eluting at RT 3.93 min in Hilic. Among them, only five features can be annotated based on the MS/MS 
Study groups
Baseline (week 0) After follow-up (week 36) Changes (week 36 - week 0)
Intervention Control p Intervention Control p
Intervention
p
Control
p p Cohen’s
(n = 60) (n = 64)
(I0-
C0) (n = 60) (n = 64) (I36-C36) (dI) (dC)
(dI-
dC) d
Age (years) 50.7 ± 7.2 49.5 ± 7.4 0.282
Gender (males/females) 6/54 11/53 0.245
Season of enrollment 
(autumn/spring) 29/31 28/36 0.609
Research centres
(Jyväskylä/Kuopio/
Helsinki)
16/19/25 15/21/28 0.917
Users of alpha/beta-
blockers 7 6
Body composition
  Body weight (kg) 85.2 ± 10.2 88.0 ± 11.7 0.181 83.5 ± 10.7 87.1 ± 11.7 0.088 −1.6 ± 3.4 0.001 −0.9 ± 2.5 0.003 0.375 −0.257
  BMI (kg/m2) 30.8 ± 3.0 31.1 ± 2.9 0.417 30.2 ± 3.2 30.8 ± 3.1 0.177 −0.6 ± 1.3 0.001 −0.3 ± 0.9 0.004 0.337 −0.280
  Waist circumference 
(cm) 100.5 ± 8.7 103.5 ± 9.3 0.074 98.0 ± 10.2 101.8 ± 10.0 0.059 −2.5 ± 4.1 <0.001 −1.7 ± 3.2 <0.001 0.347 −0.219
  Body fat (%) 39.2 ± 5.9 38.9 ± 6.5 0.869 38.1 ± 6.3 38.5 ± 6.6 0.587 −1.2 ± 2.1 <0.001 −0.4 ± 2.2 0.017 0.136 −0.331
Alcohol usage (% users) 58.3 65.6 0.237 41.7 60.9 0.002 −16.6 <0.001 −4.7 0.286 0.107
AUDIT-C scorea 3.2 ± 2.1 3.9 ± 2.4 0.134 2.7 ± 2.00 3.6 ± 2.3 0.039 −0.5 ± 1.1 <0.001 −0.3 ± 1.7 0.026 0.493 −0.112
Smoking (% smokers) 0.787 0.781 1.000 0.206
  Never smoked 58.3 53.1 60.0 56.3 1.7 3.2
  Regularly 6.7 9.4 5.0 7.8 −1.7 −1.6
  Randomly 6.7 6.3 5.0 6.3 −1.7 0
  Quit smoking 28.3 31.3 30.0 29.7 1.7 −1.6
Physical activity
  LTPA (MET h/d)b 3.68 ± 2.94 2.92 ± 2.92 0.054 4.27 ± 3.26 2.86 ± 2.73 0.004 0.59 ± 3.48 0.521 −0.06 ± 2.20 0.412 0.912 0.230
Table 1. Changes of the participants’ body composition and lifestyle indicators. Unless indicated otherwise, 
presented values are mean ± SD. Cohen’s D indicates the differences between changes in the intervention 
and the control groups, divided by the mean of the standard deviation of the changes within both groups. 
P-values within groups and between groups were tested using Wilcoxon signed-rank and Mann-Whitney U 
tests, respectively. Group proportion was compared using Chi-Square test for differences between groups. For 
differences within the group, McNemar and marginal homogeneity test were used for the proportion of alcohol 
and smoking users, respectively. P < 0.05 were considered significant (printed in bold). aAUDIT-C: Alcohol 
Use Disorders Identification Test-Consumption. bLTPA: Leisure-time physical activity, estimated using the 
metabolic equivalent (MET) hour per day.
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spectra. One metabolite was LPC(P-18:0) which also had p < 0.05 for interaction between time and intervention, 
and one was a PC dimer that eluted early in the Hilic so that it was discarded due to low reliability of MS/MS data 
for identification purpose. Noteworthy, 9 of these 12 lipids without any hit from the database search for the mass, 
eluted at 5–6 mins in RP column, which was quite unusual for such large molecules. Based on the available MS/
MS spectra of two of those, these molecules had neutral losses of 17 from the precursor ion and neutral losses of 
44 from the product ions. Also, the similar fragments with m/z 133.085 were observed in both features. 7 out of 
9 lipids were doubly-charged, which may indicate another polar head for this class of lipid, e.g. glyco- or amino-
lipids. However, due to lack of features’ MS/MS spectra and reference spectral library, the annotation could not 
continue.
The correlation analysis showed a positive association between these features and stress percentage (Fig. 3). 
Further, they correlated negatively with relaxation percentage and stress balance during sleep, and AAQW, which 
indicated a positive association with psychological flexibility. Also, we observed the negative correlations between 
these features and body fat, hsCRP, IL-1Ra, and adiponectin.
Discussion
From the 8-week Elixir lifestyle intervention aimed to improve well-being, we profiled the fasting plasma metab-
olites of volunteers participated in the face-to-face intervention group and the control group for this substudy. 
Compared to controls, the intervention group had a more pronounced improvement in psychological well-being, 
indicated by higher relaxation and lower stress indices, as well as lower AAQW, referring to higher psychological 
flexibility24. Despite the lack of intervention effect on the metabolic profile, we showed the correlation between 
some phosphatidylcholines as well as another class of unidentified lipids and markers of stress, recovery, body 
composition, and inflammation.
Study groups
Baseline (week 0) After follow-up (week 36) Changes (week 36 - week 0)
Intervention Control p Intervention Control p
Intervention
p
Control
p p Cohen’s
(n = 53) (n = 58)
(I0-
C0) (n = 53) (n = 58) (I36-C36) (dI) (dC)
(dI-
dC) d
Subjective indicators of psychological well-being
  Perceived Stress Scale 
(PSS) 25.1 ± 7.9 26.1 ± 7.8 0.615 20.1 ± 8.1 22.9 ± 9.4 0.133 −5.0 ± 9.1  < 0.001 −3.2 ± 9.0 0.007 0.271 −0.220
  AAQWa 84.1 ± 19.8 87.6 ± 21.3 0.285 72.0 ± 20.8 83.0 ± 23.8 0.012 −12.4 ± 14.9  < 0.001 −6.2 ± 13.0 0.004 0.013 −0.554
Objective indicators of psychological well-being
  Stress Balance during 
Sleep 0.43 ± 0.44 0.26 ± 0.45 0.047 0.39 ± 0.51 0.19 ± 0.50 0.017 −0.05 ± 0.64 0.935 −0.09 ± 0.62 0.305 0.443 0.054
  Stress Index 167.7 ± 40.4 165.9 ± 67.2 0.320 166.3 ± 42.6 164.2 ± 51.9 0.531 −4.1 ± 19.3 0.134 5.8 ± 29.9 0.037 0.014 −0.400
  Relaxation Index 80.2 ± 7.9 82.6 ± 9.2 0.056 80.7 ± 7.9 83.0 ± 8.51 0.094 0.8 ± 5.4 0.012 0.1 ± 3.0 0.881 0.039 0.162
  Recovery Index 69.1 ± 33.7 71.4 ± 27.2 0.366 70.0 ± 32.0 70.9 ± 27.4 0.654 2.1 ± 22.1 0.361 −2.5 ± 20.4 0.176 0.141 0.218
  Relaxation percentage 26.5 ± 8.9 23.1 ± 8.9 0.031 26.5 ± 12.0 22.6 ± 11.1 0.103 0.6 ± 15.0 0.762 −0.7 ± 13.1 0.386 0.389 0.092
  Stress Percentage 47.5 ± 10.0 50.2 ± 10.9 0.295 50.8 ± 11.9 51.9 ± 13.6 0.781 2.7 ± 14.0 0.096 1.5 ± 12.8 0.315 0.657 0.088
  Average RMSSDb 25.0 ± 11.5 26.9 ± 11.1 0.167 25.4 ± 9.2 27.6 ± 12.4 0.387 1.5 ± 5.8 0.033 0.4 ± 8.1 0.515 0.052 0.160
Subjective sleep-related parameters
  Sleep duration (hours) 6.06 ± 1.03 5.74 ± 1.17 0.189 5.90 ± 1.21 6.09 ± 1.16 0.523 −0.18 ± 1.13 0.335 0.29 ± 1.10 0.143 0.099 −0.419
  Sleep efficiency (%)c 80.1 ± 11.2 74.9 ± 13.0 0.035 80.2 ± 12.6 78.9 ± 11.7 0.270 −0.2 ± 13.4 0.838 3.5 ± 13.8 0.043 0.234 −0.273
  Sleep qualityd 3.20 ± 0.51 3.34 ± 0.49 0.213 3.39 ± 0.60 3.38 ± 0.58 0.973 0.20 ± 0.63 0.056 0.04 ± 0.52 0.501 0.312 0.294
Inflammation markerse
  HMW adiponectin 
(µg/ml) 5.77 ± 3.75 6.02 ± 5.79 0.480 6.10 ± 4.35 5.83 ± 4.76 0.516 0.33 ± 1.71 0.108 −0.19 ± 2.08 0.567 0.392 0.272
  IL-1Ra (ng/ml) 0.40 ± 0.19 0.46 ± 0.21 0.111 0.38 ± 0.19 0.41 ± 0.17 0.107 −0.02 ± 0.14 0.298 −0.05 ± 0.17 0.140 0.719 0.189
  hsCRP (mg/l) 3.66 ± 6.04 3.88 ± 5.85 0.320 2.30 ± 2.69 4.13 ± 7.33 0.098 −1.37 ± 4.98 0.023 −0.25 ± 8.43 0.952 0.176 −0.242
Table 2. Changes of the participants’ indicators of psychological well-being, sleep parameters, and 
inflammation markers, excluding the users of alpha- and beta-blockers medication. Unless indicated otherwise, 
presented values are mean ± SD. Cohen’s D indicates the differences between changes in the intervention 
and the control groups, divided by the mean of the standard deviation of the changes within both groups. 
P-values within groups and between groups were tested using Wilcoxon signed-rank and Mann-Whitney U 
tests, respectively. P < 0.05 were significant (printed in bold). aAAQW: weight-related Acceptance and Action 
Questionnaire, a higher score indicates psychological inflexibility related to body weight and appearance. 
bAverage RMSSD: the average of root-mean-square of successive differences between beats within 5-minute 
intervals during sleeping time. cSleep efficiency: the ratio of total sleep duration to the total time spent in bed. 
dSleep quality was presented as the mean of 5-scale sleep quality (1 is the worst, 5 is the best) from day 1–7 
since study visits. eHMW adiponectin: high-molecular-weight adiponectin; IL-1Ra: interleukin-1-receptor 
antagonist; hsCRP: highly-sensitive C reactive protein.
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Unlike a previous study in rats with chronic mild stress25, we found lower LPCs in the intervention group 
following the lifestyle intervention, with different correlations with physiological parameters based on the acyl 
chains. The stress relief, as indicated by a lower stress index, was positively associated with the suppressed LPCs 
in the intervention group: LPC(14:0), (16:1), and (20:4) (Cluster B, Fig. 2). LPC(14:0) and (16:1), in particular, 
also inversely correlated with increased relaxation and recovery indices, along with RMSSD which may imply 
activated parasympathetic nervous system to counterbalance stress26. Previously, LPC(14:0) and (16:1) have been 
associated with arterial stiffness27. Other suppressed PCs, including LPC(22:5), PC(16:0/16:1), and PC(18:0/20:3) 
(Cluster C, Fig. 2), correlated positively with the reduction in adiposity and inflammation, and inversely with 
increased relaxation index. The positive correlation between these PCs with the AAQW scores may also link to 
the improvement of weight-related psychological flexibility in the intervention group since the lower AAQW 
score reflects higher psychological flexibility. Noteworthy, these (L)PC indicative for stress and inversely for 
recovery contained medium-chain saturated fatty acids (SFA), particularly 16:0 and 18:0. Previously, phospho-
lipids with increased saturation have been shown to enhance cellular stress signaling28. Since these (L)PC showed 
potential as biomarkers of stress, adiposity, and inflammation which, in this study, were reduced by the lifestyle 
intervention, this finding hence may support the hypothesis of shared mechanisms between psychological and 
physiological stress responses8.
In addition to the positive association between LPC(20:4) with stress index, the free fatty acid (20:4) form, has 
been previously suggested as a marker of depression and stress in human18 and rats25, respectively. LPC(22:5) in 
the intervention group was also associated with inflammation and adiposity. Interestingly, another PC containing 
Figure 2. Correlation matrix between metabolites and the physiological and psychological parameters 
of the study participants. The up-regulated metabolites had a positive estimate, indicating an increase in 
the intervention group or a reduction in the control group, while the down-regulated ones had a negative 
estimate (reduced in the intervention group or elevated in the control group). Red blocks indicate a positive 
correlation, and blue blocks indicate otherwise. The size of the circle indicates –log p. AAQW: Acceptance and 
Action Questionnaire for Weight-related difficulties; AUDIT-C: Alcohol Use Disorders Identification Test-
Consumption BMI: body mass index; HMW adiponectin: high-molecular-weight adiponectin; hsCRP: highly 
sensitive C-reactive protein; IL-1Ra: interleukin-1 receptor antagonist; (L)PC: (lyso)phosphatidylcholine; LTPA: 
leisure-time physical activity; PSS: Perceived Stress Scale; RMSSD: Root Mean Square of the Successive R-R 
Differences; RP: reversed-phase.
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polyunsaturated fatty acid (PUFA), PC(18:1/22:6), seemed elevated in the intervention group and correlated pos-
itively with the improvement of relaxation and recovery indices along with increased RMSSD. Hence, the PUFA 
that was bound in PC seemed to favour relaxation and recovery, whereas PUFA in LPC seemed to indicate stress, 
inflammation, adiposity, and inversely for relaxation and recovery. Although we cannot draw any causality in this 
study, this result might imply the possible role of PUFA-containing PC as a proxy of anti-inflammatory activity.
Another group that deserves attention is plasmalogens. The elevated plasmalogens PC(P-18:0/20:4) and PC(P-
18:0/22:6) were inversely associated with adiposity indicators and AAQW, which related to better body compo-
sition and psychological flexibility. Also, LPC(P-18:0) was inversely associated with adiposity and inflammation 
markers hsCRP and IL-1Ra. The biological roles of plasmalogens as membrane component and anti-oxidant, also 
in the regulation of cell signalling, immune response, and cholesterol efflux, have been reviewed29. Further studies 
are thus required to segregate the structural and signalling functions of PC, containing either long-chain PUFA or 
medium-chain SFA, n-3 or n-6, based on their structure as LPCs or plasmalogens, in free or bound forms, along 
with relevant enzymes and metabolic pathways within a close framework of inflammation, adiposity, psycholog-
ical and physiological stress responses.
Noteworthy, we did not observe any correlation between the two metabolites exhibiting the most significant 
difference in the metabolite profiling assay, namely retinol and epsilon-caprolactam with other parameters, except 
the negative relationship between epsilon-caprolactam with BMI and body fat percentage. One of the reasons 
behind the large effect size of retinol (Cohen’s D = −0.59, p = 0.002) could be the more substantial reduction of 
vitamin A intake in the intervention group than one in the control group, though it did not reach statistical sig-
nificance (Supplementary Table S3). Therefore, we want to underline that in this free-living design, the volunteers 
were daily exposed to multiple stressors or other lifestyle factors which may alter the metabolic profile. In other 
words, the observed differences in the metabolic profiles could be attributable to other factors. The employed 
correlation analysis hence served as a verification step if the metabolite of interest was related to the psychological 
or physiological outcome measures that became the point of interest in this present study. The observation of sev-
eral metabolites belonging to the same compound classes (e.g., PC) could also confirm the observed association. 
Using physical activity as an example, Table 1 showed that physical activity did not significantly change in either 
of the group, and the changes did not differ between the two groups. Among all 17 identified PC, only LPC(17:0) 
and (20:3) were shown to correlate with physical activity (Fig. 2), which may diminish the contribution of phys-
ical activity on the fasting plasma profile of the participants in this study. Nevertheless, our results here require 
more in-depth investigations to untangle the contribution of lifestyle factors to obtain the objective biomarker of 
stress, e.g., in a more controlled experimental design or various population groups with different lifestyle factors.
We also observed a more pronounced effect of time on the metabolic profile regardless of the intervention 
(Supplemental Fig. S1), which may refer to the improved markers of body composition (Table 1) and subjec-
tive indicators of psychological well-being both in the intervention and control groups (Table 2). Although the 
annotation could not continue due to lack of compounds’ MS/MS and reference spectra, particular lipids pre-
dominated the distinctive features for the time. The available MS/MS spectra from two features may imply a class 
Figure 3. The correlation analysis between physiological and psychological parameters with 13 features 
differential for time (FDR < 0.05) which increased in both intervention and control groups. *Indicates 
metabolite that also differed for interaction between time and intervention, and ¤ indicate metabolites which 
have been annotated based on the MS/MS spectra. Red blocks indicate a positive correlation, and blue blocks 
indicate otherwise. The size of the circle indicates –log p. AAQW: Acceptance and Action Questionnaire for 
Weight-related difficulties; AUDIT-C: Alcohol Use Disorders Identification Test-Consumption BMI: body mass 
index; HILIC: hydrophilic interaction column; HMW adiponectin: high-molecular-weight adiponectin; hsCRP: 
highly sensitive C-reactive protein; IL-1Ra: interleukin-1 receptor antagonist; LPC: (lyso)phosphatidylcholine; 
LTPA: leisure-time physical activity; PSS: Perceived Stress Scale; RMSSD: Root Mean Square of the Successive 
R-R Differences; RP: reversed-phase.
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of lipids with polar side-chain, and which were also associated with adiposity and stress indicators. This finding 
hence calls for targeted measurement of this specific class in future investigation on the metabolites associated 
with both physiological and psychological stress indicators. However, considering that these features increased 
similarly both in intervention and control groups, they may represent the contribution of other factors or poten-
tial confounders that may explain the improvement in the control group (Table 1), which may not be relevant to 
the study objective or be confounded by the selection bias. One example could be the weight-loss effort during the 
time interval by the control group who had the intention to lose weight21, as proven by the voluntary enrollment.
The strengths of this study include the novel application of a non-targeted metabolomics approach to assess 
the metabolic profile of participants showing psychological stress improvement. This application hence may 
unveil new inter-disciplinary research in eating behaviour, psychology, or other related fields. The multi-centre 
lifestyle intervention in working-aged adults with psychological stress and high risk to metabolic syndrome 
resembled the real-life setting with a higher likelihood of prolonged intervention and smooth translation to pub-
lic health policy. The population was quite homogenous consisting of overweight-to-obese Finnish individuals, 
minimising the potential confounders from a genetic, culturally-linked dietary pattern, or other environmental 
factors, but may also limit the generalisability of findings to other populations.
We also admit other limitations in this study. The effect of different locations and seasons have been included 
in the statistical models as random effects, but we cannot exclude their total potential contribution to the meta-
bolic profile. The inclusion of both men and women in this study may attenuate the observed intervention effects 
due to sex-based differences in stress indicators30 and hormonal cycle, especially for women. The given interven-
tion did not contain education on a healthy diet or physical activity19, allowing the behavioural changes to what 
they believed would be beneficial for them, instead of a standardised measure of a specific factor. Other potential 
sources of bias include rather highly-educated Finns, mostly non-smokers, and inter-individual differences in 
response to stress. The subjective assessment of psychological well-being using PSS and AAQW questionnaires 
may introduce reporting bias. Thus, we also included the results from objectively-measured stress indicators 
derived from HRV measurement. This measurement, however, may also add other potential sources of confound-
ers, including medication. Consequently, we excluded users of alpha- and beta-blockers in the statistical analyses 
that contained HRV-based parameters.
End measurement at the follow-up was both strength and limitation of the study. The interval between the 
end of the intervention (week 10) and follow-up (week 36) allowed the volunteers to maintain the newly-adopted 
lifestyle after the intervention, hence enabled detection of longer-term changes, including chronic inflammatory 
markers and stress markers. Based on that aim, we did not include potential acute stress markers or the possible 
effect of daily dietary intake in this particular substudy. However, the 26-week period from the end of the inter-
vention to the follow-up might allow lifestyle modification in participants of both groups, which may attenuate 
the observed effect of the intervention.
In conclusion, we investigated a panel of fasting plasma metabolites that changed during a lifestyle interven-
tion aimed to improve well-being, along with an improvement in psychological well-being and body composition. 
Despite the lack of intervention effect on the metabolite profile, we found correlations between various phospho-
lipids, especially those belonging to the PC class, with body composition, stress, and recovery parameters, such as 
PC-containing PUFA with recovery and inversely with adiposity and inflammation. These findings hence allow 
us to generate hypothesis on specific metabolites and the potentially relevant metabolic processes which could be 
involved in the systemic response to stress relief. Our findings thus provide supportive evidence for further inves-
tigations aiming to unveil the role of the identified phospholipids and another class of unidentified lipids in the 
molecular interplay between psychological well-being and metabolic health, including other related factors such 
as body composition and inflammation. Future effort to illuminate the causal mechanisms linking psychological 
and metabolic health is thereby encouraged.
Methods
Study population and samples selection. 339 overweight or obese individuals from Helsinki, Jyväskylä, 
and Kuopio with self-perceived and reported stress symptoms participated in the Elixir randomised-controlled 
lifestyle intervention study, in September 2012-June 2013 and January-October 201319. They were 25–60 years 
of age, had self-reported BMI 27–34.9 kg/m2, psychological stress ≥3 points according to the General Health 
Questionnaire (GHQ-12)31, and access to an internet-connected computer. The participants were randomised 
to either one of the following four parallel groups for eight weeks: a web-guided Cognitive Behavioural Therapy 
(CBT)-based intervention, an Acceptance and Commitment Therapy (ACT) guided by a mobile application, an 
ACT-based intervention with face-to-face group meetings, or a control group19 (Fig. 1). The overall aim of the 
whole intervention was to evaluate the effect of these interventions on psychological flexibility, risk factors of 
metabolic syndrome, and general well-being19. The determination of sample size, randomisation procedure, and 
complete description of the outcome measures have been described in the protocol paper19.
The participants assigned to the face-to-face group meetings showed the most pronounced improvement of 
psychological flexibility during the intervention23. They were therefore included in this secondary analysis aimed 
to investigate the metabolic profile indicative for psychological well-being, along with the participants in the 
control group. After exclusion of non-compliant participants (attended less than four sessions of the face-to-face 
group meetings, drop-out due to personal reasons, or loss to follow-up), 64 and 60 volunteers from control and 
face-to-face intervention groups, respectively, completed the follow-up measurement (Fig. 1).
Ethics. The protocol of Elixir study was approved by the ethics committee of the Central Finland Health Care 
District with the reference number 7U/2012 and was performed following the Declaration of Helsinki. The study 
was registered with ClinicalTrials.gov with identifier NCT01738256. All participants signed written informed 
consent during the laboratory examination at baseline. All data were handled anonymously.
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Study visits. The participants came to the study centres after an overnight fast at baseline (week 0), after the 
intervention (week 10), and follow-up (week 36), for venous blood sampling and measurement of body com-
position (body weight, height, body fat percentage, and waist circumference)19. Inflammation markers hsCRP, 
IL-1Ra, and high molecular weight adiponectin (HMW-adiponectin) were measured in the serum samples19. 
Metabolic profiling was performed on plasma samples obtained at the baseline (week 0) and follow-up (week 36) 
measurement (Fig. 1), comprising 248 samples for metabolomics analysis altogether. Plasma samples were stored 
at −80 °C until the laboratory procedure.
LC-MS analysis. We used the in-house developed web application, Wranglr (https://github.com/antonvsdata/
wranglr) to automate samples recoding, randomisation, and worklists generation for LC-MS experiments. As the 
input, Wranglr takes a spreadsheet containing necessary information about the samples such as sample identifier 
and study group. The output is worklists for LC-MS software containing quality control (QC) and autoMS/MS 
samples along with a processed spreadsheet containing sample information, injection order, plate positions, data file 
paths, and other relevant information. Wranglr is implemented in R 3.4.032 using the Shiny package version 1.0.333.
100 µl sample that has been properly thawed on ice was mixed with 400 µl of LC-MS-grade acetonitrile to 
obtain protein-free filtrate, while a small part of each sample was pooled down as a QC sample, as previously per-
formed34. Liquid chromatography platform consists of 1290 Infinity Binary UPLC system (Agilent Technologies, 
Santa Clara, CA, USA) using both reverse-phase (RP, Zorbax Eclipse XDB-C18, particle size 1.8 µm, dimensions 
of 2.1 × 100 mm, Agilent Technologies, USA) and hydrophilic interaction chromatography (HILIC, Acquity 
UPLC® BEH Amide 1.7 µm, 2.1 × 100 mm, Waters, Ireland) columns with previously established protocol35. 
The coupling mass spectrometry was a 6540 UHD Accurate-Mass Q-TOF LC/MS (Agilent Technologies, Santa 
Clara, CA, USA) employing both positive and negative electrospray ionisation (ESI) modes36. Four precursor ions 
with the highest abundance were selected for MS/MS fragmentation with collision energies 10, 20, and 40 V. The 
low-abundance signals of interest which were not selected for fragmentation underwent targeted MS/MS analysis 
as described in the Supplementary Method. Due to a technical event, eight samples were not included in the RP 
positive mode, thereby the metabolic features from those eight samples were only supported by measurement in 
HILIC (both positive and negative modes) and RP negative mode.
Initial peak-picking and alignment. The peak-picking procedure was initially performed using “Find 
by Molecular Feature” algorithm in Agilent MassHunter Qualitative Analysis B.07.00 (Agilent Technologies). 
Centroid spectra peaks higher than 400 counts were subjected against ion restriction: negative ions [M-H]−, 
[M + Cl]−, and [M + HCOO]−, and positive ions [M + H]+ and [M + Na]+. The data (.cef) files were then aligned 
and combined into a reference (.cef) file against which the original raw data was reanalysed in Mass Profiler 
Professional (MPP) software version 2.2 (Agilent Technologies). For this recursive analysis, we restricted the 
compounds with a maximum mass of 1000 Da and minimum absolute abundance of 5000 counts in negative 
modes or 8000 counts in positive ones. The tolerance for compound mass was 15 ppm ± 2 mDa, retention 
time ± 0.15 min, and symmetric expansion value ± 10 ppm for chromatograms. The output was re-exported to 
MPP for peak alignment and data cleanup. Subsequent filtering included only features that were present in at least 
50% of samples in at least one study group. As the results, we got 2372 and 504 features from HILIC, and 3274 and 
1334 features from RP, in positive and negative mode, respectively. The combined data matrix, which consisted 
of 7484 features from 248 samples with respective raw peak areas henceforth underwent data pre-processing.
Data preprocessing: quality control and drift correction of metabolomics data. Before statistical 
analysis, signals that were present in less than 80% of the samples in all study groups and with detection rate less 
than 70% of the pooled QC samples were excluded. Signal quality was measured using error metrics defined pre-
viously37. The remaining signals were corrected for the drift pattern caused by the long LC-MS run. Regularised 
cubic spline regression was fit separately for each signal on the QC samples38. The smoothing parameter was 
chosen from an interval between 0.5 and 1.5 using leave-one-out cross-validation to prevent overfitting. The 
performance of the drift correction was assessed using robust non-parametric estimates of the relative standard 
deviation of QC samples (RSD*) and D-ratio*37 as quality metrics. Drift correction was only applied if the value 
of both quality metrics decreased, indicating enhanced quality. Otherwise, the original signal was retained.
After the drift correction, QC samples and low-quality signals were also removed before imputation and nor-
malisation to prevent them from biasing the procedures. Signals were kept if their RSD* was <20% and their 
D-ratio < 40%, or if all of their classic RSD, RSD* and basic D-ratio < 10%. The missing values in the high-quality 
signals were imputed using random forest imputation implemented in the R package missForest version 1.439. 
The out-of-bag error estimates were <0.1 for all the modes, indicating high-quality imputation. Following this 
procedure, we retained 1020 and 267 metabolic features from HILIC, and 1073 and 440 features from RP, in 
positive and negative mode, respectively. Signals were hereafter normalised using inverse-rank normalisation to 
approximate a normal distribution. The normalised data of each mode were then combined to a matrix of total 
2800 features for statistical analysis.
Other measurements. Because retinol had p < 0.05 for interaction between time and intervention, we 
hence checked if vitamin A intake also differed between the groups. Vitamin A intake was assessed based on 
a 48-hour dietary recall, including the portion size and preparation methods, performed by trained nutrition-
ists. Alcohol consumption during the past six months was estimated using the Finnish version of Alcohol Use 
Disorders Identification Test-Consumption (AUDIT-C) questionnaire40. The LTPA was assessed using a ques-
tionnaire covering leisure-time and commuting activity and presented as metabolic equivalent (MET) multiplied 
by duration in hours (h)19,41,42. The sleep quality was based on a 7d-sleep diary43, with 1 indicating the worst and 5 
indicating the best quality. The sleep efficiency was obtained based on an actigraphy measurement for one week, 
by dividing total sleep duration by the total time in bed, in percent19.
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The assessment of psychological well-being employed questionnaire-based subjective indicators19. The meas-
urement of stress used a 14-item PSS44 questionnaire to let the participants themselves indicate how stressful 
they had perceived their life during the previous month. A higher PSS score indicates a higher degree of per-
ceiving one’s life stressful. Additionally, psychological flexibility was measured using Acceptance and Action 
Questionnaire for Weight-related difficulties (AAQW)24, with a lower score indicating higher psychological 
flexibility.
The objective assessment of stress and relaxation relied on a wearable HRV-monitoring device (Firstbeat 
Technologies, Jyväskylä, Finland). The participants were instructed to wear the device for three consecutive days 
and nights, consisting of two weekdays and one weekend day. Stress, recovery, and relaxation indices, stress and 
relaxation percentages, and stress balance during sleep were calculated using Firstbeat patented algorithms45. In 
brief, the recovery index estimated one’s recovery within 4 hours during sleep time, starting 30 minutes after going 
to bed. Stress and relaxation indices give absolute value characterising the magnitude of stress and relaxation, 
respectively. Conversely, stress and relaxation percentage calculate the percentage of stress and relaxation, respec-
tively, within the measurement period. Stress balance during sleep gives a proportion between the time of stress 
and relaxation during sleep time (based on the description of the variables from Firstbeat Technologies). Based on 
the recorded HRV, the device also directly computed the RMSSD, which indicate the mean changes of the interval 
between two subsequent beats46. The average RMSSD was derived by calculating the average of RMSSD for each 
5-minute interval during sleeping time.
Statistical analysis for metabolomics data. A linear mixed model was fit separately for each metab-
olite to spot the differential metabolites using R packages lme447 and lmerTest48. The effects of the intervention 
and time, along with their interaction, were modelled as fixed effects, with the interaction between intervention 
and time as the main result. The interaction term reflects different change during the intervention between the 
control and intervention group. Random effects included volunteers nested inside centres and the effect of sea-
son, crossed with the previous effects. All random effects were modeled as random intercepts, tested using the 
likelihood ratio test. The significance of the regression coefficients was tested using a t-test with Satterthwaite’s 
approximation for degrees of freedom. Confidence intervals were constructed using parametric bootstrapping 
percentile intervals with 1000 simulations. Benjamini-Hochberg false discovery rate (FDR) was performed for 
multiple testing correction on the unannotated 2800 features (Supplementary Table S1). Feature screening was 
then performed based on the unadjusted p, as we mainly use the p-value to rank metabolites for potential discov-
eries and hypothesis generation, not to prove statistically significant effects. All statistical analyses for metabolite 
signals were performed using R version 3.4.232.
Identification of compounds. The screening of features for the interaction between time and intervention 
was performed with the following criteria: unadjusted p < 0.05, mass < 1000 Da, and retention time > 0.5 min. 
After filtering, 104 features were subjected to the identification based on reporting guidelines from Metabolomics 
Standard Initiative49. Compounds with level I matched references in the in-house library built by running com-
mercial standard in the same instrument and experimental condition. Level II includes compounds with match-
ing mass, ion charge, and spectra of fragmented ions from online databases, such as METLIN50, the Human 
Metabolome Database51 (HMDB) version 3.6, or LIPID MAPS52. Identification of phospholipids was performed 
based on ion fragmentation pattern in the positive mode53, while the acyl-chain was determined based on the for-
mate adduct of the corresponding compounds in the negative mode54,55. Level III includes unknown compounds 
with the prediction of compound classes or functional groups based on the MS/MS fragments. Level IV includes 
all unidentified metabolites. Eventually, 27 differential metabolites (7 from HILIC positive, 7 from RP negative, 
and 13 from RP positive), with their respective MS/MS fragments, were reported in Supplementary Table S1. 
The annotation step for the features differential for time was done with similar manner and following criteria: 
FDR < 0.05, RT > 1 min.
Pathway analysis. The identified peaks differential for the interaction between time and intervention with 
level I and II identification were included in the “Pathway Analysis” module in MetaboAnalyst 4.056, using their 
HMDB ID as the identifiers (Supplementary Table S4), except carnitine (11:1) and epsilon-caprolactam with 
lacking and unrecognized HMDB IDs, respectively. The analyses were then performed for the remaining 20 
metabolites with Homo sapiens KEGG as the reference library and all compounds in the selected pathways as 
the reference metabolome. The over-representation analysis was performed using the Fisher exact test and the 
pathway topology using relative-betweenness centrality.
Statistical analyses for other parameters. Due to the possible effects of medications containing alpha- 
and beta-blockers on heart rate, we excluded the volunteers using such medicines in all analyses using HRV-based 
parameters. Finally, 53 and 58 volunteers from the intervention and control groups, respectively, were included 
in analyses concerning HRV-based parameters (Fig. 1). After this exclusion, the data from both intervention and 
control groups at both baseline and follow-up time points were merged and included for the Pearson correlation 
analysis between the identified metabolites and the psychological and physiological parameters. The correlation 
patterns were visualised in a heatmap, where the metabolites, psychological, and physiological parameters were 
ordered using hierarchical clustering with Euclidean distance and Ward’s hierarchical clustering criterion (ward.
D2)57. The effect sizes were calculated using Cohen’s D, derived by subtracting the mean difference in change 
(dI-dC) in the intervention (subscript I) and control (subscript C) groups then dividing it with the mean of the 
standard deviation of the changes in both groups.
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where: dI and dC are the averages of the metabolite changes between the follow-up measurement (week 36) and 
baseline (week 0) in the intervention (I) group and the control (C) group, respectively. An absolute effect size of 
<0.25 were considered small, 0.25–0.5 medium, and >0.5 large32,58.
The differences between groups were analysed using Pearson’s Chi-Square for categorical variables. McNemar 
was used to comparing the changes within the dichotomous group proportion of alcohol users (users or 
non-users). A similar comparison was performed for smokers using the marginal homogeneity test for nominal 
data with more than two categories. The changes within (between week 0 and week 36) and between groups for 
continuous variables were compared using Wilcoxon signed-rank and Mann-Whitney U tests, respectively (IBM 
SPSS Statistics 25, International Business Machines Corporation). P < 0.05 was considered significant.
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